文献速递肺血管病与心包/心肌炎瓣膜病与结构性心脏病

先天性心脏病相关肺动脉高压的三联血管扩张剂治疗

Triple vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease.
PubMed 文献 · Heart · 2024-02-12

本研究回顾性纳入60例已接受最大剂量双联治疗的先心病相关肺动脉高压患者,加用前列环素类三联治疗并随访2年。结果显示6分钟步行距离、功能分级和NT-proBNP均改善,副作用多为轻度可管理,非艾森曼格综合征及三尖瓣前缺损者获益更明显。

要点

  • 双联基础上加用前列环素类三联治疗可改善先心病相关肺动脉高压患者运动耐量。
  • 功能分级和NT-proBNP在2年随访中持续改善,副作用多为轻度可管理。
  • 非艾森曼格综合征及三尖瓣前缺损患者获益更明显。

核心结论

  • 含前列环素类的三联治疗对先心病相关肺动脉高压患者安全有效,2年内改善功能分级、6分钟步行距离和NT-proBNP水平。

研究设计与样本

  • 回顾性队列研究,纳入60例已接受最大剂量双联治疗并规律随访的先心病相关肺动脉高压患者,中位年龄41岁,68%为女性。

主要发现

  • 三联治疗1年后6分钟步行距离显著改善(406 vs 450;p=0.0027),并在2年随访时维持。
  • 1年时79%患者功能分级改善,2年时76%保持稳定。
  • 2年时NT-proBNP显著下降,平均降低199 ng/L。
  • 33.3%患者出现副作用,但多为轻度且可管理。
  • 亚组分析显示非艾森曼格综合征及三尖瓣前缺损患者获益更大。

临床怎么用

  • 对已接受最大剂量双联治疗仍可优化的先心病相关肺动脉高压患者,可考虑加用前列环素类三联治疗并定期随访。
  • 治疗中关注副作用,多数为轻度可管理,非艾森曼格综合征及三尖瓣前缺损患者可能获益更明显。

局限性

  • 回顾性单中心队列研究,样本量60例,结果需更大规模前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study assessed the long-term effects of triple therapy with prostanoids on patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), as there is limited information on the safety and efficacy of this treatment approach. METHODS: A retrospective cohort study was conducted on patients with PAH-CHD who were actively followed up at our centre. All patients were already receiving dual combination therapy at maximum doses. Clinical characteristics, including functional class (FC), 6-minute walking test distance (6MWTD) and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, were documented before initiating triple therapy and annually for a 2-year follow-up period. RESULTS: A total of 60 patients were included in the study, with a median age of 41 years and 68% being women. Of these, 32 had Eisenmenger syndrome, 9 had coincidental shunts, 18 had postoperative PAH and 1 had a significant left-to-right shunt. After 1 year of triple combination initiation, a significant improvement in 6MWTD was observed (406 vs 450; p=0.0027), which was maintained at the 2-year follow-up. FC improved in 79% of patients at 1 year and remained stable in 76% at 2 years. NT-proBNP levels decreased significantly by 2 years, with an average reduction of 199 ng/L. Side effects were experienced by 33.3% of patients but were mostly mild and manageable. Subgroup analysis showed greater benefits in patients without Eisenmenger syndrome and those with pre-tricuspid defects. CONCLUSIONS: Triple therapy with prostanoids is safe and effective for patients with PAH-CHD, improving FC, 6MWTD and NT-proBNP levels over 2 years. The treatment is particularly beneficial for patients with pre-tricuspid defects and non-Eisenmenger PAH-CHD.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Luna-Lopez R, Segura de la Cal T, Sarnago Cebada F, et al. Triple vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease. Heart. 2024. PMID: 37903556. doi:10.1136/heartjnl-2023-323015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。